Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

Bruce A. Sullenger, PhD

Blood (2019) 134 (Supplement_1): SCI-16.

https://doi.org/10.1182/blood-2019-121056

Published: 2019

Journal Articles

The Anti-Factor XII Antibody AB052 Is Antithrombotic without Hemostatic Impairment in a Primate Model of Extracorporeal Membrane Oxygenation

Michael Wallisch, PhD, Erik I Tucker, PhD, Christina U Lorentz, PhD, Jennifer Johnson, RLATG, Marschelle R Carris, BA, Owen JT McCarty, PhD, Monica T Hinds, PhD, András Gruber, MD

Blood (2017) 130 (Supplement 1): 236.

https://doi.org/10.1182/blood.V130.Suppl_1.236.236

Published: 2017

Journal Articles

RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit

Ruwan Gunaratne, MA, James Frederiksen, MD, Nabil K. Thalji, BS, Michelle D Ho, Gowthami M Arepally, MD, Rodney M. Camire, PhD, Bruce A. Sullenger, PhD

Blood (2016) 128 (22): 3823.

https://doi.org/10.1182/blood.V128.22.3823.3823

Published: 2016

Journal Articles

MP4, a Human Hemoglobin Modified with Maleimide-Peg, Reduces Sickling of Red Blood Cells in an In Vitro Model.

Robert Winslow, MD, Mariana Oliva, Marcos Intaglietta, PhD, Kim Vandegriff, PhD, Dale Baker, PhD, Ashok Malavalli

Blood (2005) 106 (11): 3798.

https://doi.org/10.1182/blood.V106.11.3798.3798

Published: 2005

Journal Articles

Argatroban for Anticoagulation during Cardiopulmonary Bypass.

Monte E. Martin, MD, Goetz H. Kloecker, MD, MSP.H., Anand Patel, MD, Damian A. Laber, MD, F.A.C.P.

Blood (2005) 106 (11): 4150.

https://doi.org/10.1182/blood.V106.11.4150.4150

Published: 2005

Journal Articles

Coronary Artery Revascularization Surgery in Hemophiliacs: Patient Experiences That Suggest the Simultaneous Use of Anticoagulant Therapy with Antihemophiliac Factor Replacement in the Perioperative Setting.

John J. McCarthy, Elham Abassi2

Blood (2004) 104 (11): 4074.

https://doi.org/10.1182/blood.V104.11.4074.4074

Published: 2004

NARROW

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

The Anti-Factor XII Antibody AB052 Is Antithrombotic without Hemostatic Impairment in a Primate Model of Extracorporeal Membrane Oxygenation

RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit

MP4, a Human Hemoglobin Modified with Maleimide-Peg, Reduces Sickling of Red Blood Cells in an In Vitro Model.

Argatroban for Anticoagulation during Cardiopulmonary Bypass.

Coronary Artery Revascularization Surgery in Hemophiliacs: Patient Experiences That Suggest the Simultaneous Use of Anticoagulant Therapy with Antihemophiliac Factor Replacement in the Perioperative Setting.

Email alerts

ASH Publications

American Society of Hematology

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents

The Anti-Factor XII Antibody AB052 Is Antithrombotic without Hemostatic Impairment in a Primate Model of Extracorporeal Membrane Oxygenation

RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit

MP4, a Human Hemoglobin Modified with Maleimide-Peg, Reduces Sickling of Red Blood Cells in an In Vitro Model.

Argatroban for Anticoagulation during Cardiopulmonary Bypass.

Coronary Artery Revascularization Surgery in Hemophiliacs: Patient Experiences That Suggest the Simultaneous Use of Anticoagulant Therapy with Antihemophiliac Factor Replacement in the Perioperative Setting.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only